老虎证券

BRIEF-Merck’S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity

Reuters
2025/05/30
BRIEF-Merck’S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity

May 30 (Reuters) - Merck & Co Inc MRK.N:

  • MERCK’S INVESTIGATIONAL ZILOVERTAMAB VEDOTIN AT 1.75 MG/KG DOSE PLUS STANDARD OF CARE SHOWED PROMISING ANTITUMOR ACTIVITY, INCLUDING COMPLETE RESPONSE RATE, IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL IN PHASE 2 PORTION OF WAVELINE-003 TRIAL

  • MERCK & CO INC - ZILOVERTAMAB VEDOTIN ACHIEVES 56.3% ORR IN RELAPSED/REFRACTORY DLBCL

  • MERCK & CO INC - ZILOVERTAMAB VEDOTIN UNDER EVALUATION IN PHASE 3 AND PHASE 2 STUDIES

Source text: ID:nBw884qGba

Further company coverage: MRK.N

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10